BAPTA-AM-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEBAPTA-AMCat.No.:HY-100545CASNo.:126150-97-8分?式:C??H??N?O??分?量:764.68作?靶點(diǎn):PotassiumChannel作?通路:MembraneTransporter/IonChannel儲(chǔ)存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:50mg/mL(65.39mM;Needultrasonic)H2O:<0.1mg/mL(ultrasonic)(insoluble)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM1.3077mL6.5387mL13.0774mL5mM0.2615mL1.3077mL2.6155mL10mM0.1308mL0.6539mL1.3077mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:≥2.5mg/mL(3.27mM);Clearsolution2.請(qǐng)依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:2.5mg/mL(3.27mM);Suspendedsolution;Needultrasonic3.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(3.27mM);ClearsolutionBIOLOGICALACTIVITY?物活性BAPTA-AM?種可透過(guò)細(xì)胞膜的鈣螯合劑(Ca2+chelator)。在HEK293細(xì)胞中，BAPTA-AM阻斷hERG，hKv1.3和hKv1.5通道，IC50分別為1.3，1.45和1.23μM[1]。IC50&TargetCa2+chelator[1]IC50:1.3μM(hERGchannel,inHEK293cells),1.45μM(hKv1.3,inHEK293cells),1.23μM(hKv1.5,inHEK293cells)[1]體外研究BAPTA-AMinhibitsneuronalCa2+-activatedK+channelcurrents,andup-regulatesthedecreasedcardiacsodiumcurrent(INa)densitybychelatingintracellularCa2+[1].BAPTA-AM(BAPTA/AM),anintracellularcalciumchelator,inducesdelayednecrosisbylipoxygenase-mediatedfreeradicalsinmousecorticalcultures.BAPTA-AMpreventsfreeradical-mediatedtoxicitypromoteapoptosisinnon-neuronalcellsandproduceabeneficialeffectinneuronalcellsbyprotectingneuronsfromischemicdamage.Inaddition,ithasbeensuggestedthatBAPTA-AMinducesalate,butnotearly,increaseofintracellularcalciuminI-IL-60neoplasticcells.Mixedcorticalcellcultures(DIV13-16)exposedto10μMBAPTA-AMfor24-or48-hrshowmoderate(45-70%)neuronalinjuryasevaluatedbyincreasedLDHreleaseintothebathingmediumafter24-48-hr.Exposureofcorticalculturesto3-10μMBAPTA-AMfor48-hrevokedose-dependentneuronaldamage[2].PROTOCOLCellAssay[1]Neuronalinjuryisquantitativelyestimatedbymeasuringlactatedehydrogenase(LDH)releasedfromdamagedcellsintothebathingmedium24-or48-hrafterthe10μMBAPTA/AMtreatment.Themorphologicalfindingsareconfirmedbystainingwithneuron-specificenolase(NSE)antibodyandtryphanblue[1].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?SignalTransductTargetTher.2022Feb16;7(1):46.?NatImmunol.2019Apr;20(4):433-446.?CellStemCell.2022Oct12;S1934-5909(22)00417-9.?NatCommun.2021May18;12(1):2915.?JExtracellVesicles.2022Oct;11(10):e12274.2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESeemorecustomervalidationsonwww.MedChemEREFERENCES[1].WieMB,etal.BAPTA/AM,anintracellularcalciumchelator,inducesdelayednecrosisbylipoxygenase-mediatedfreeradicalsinmousecorticalcultures.ProgNeuropsychopharmacolBiolPsychiatry.2001Nov;25(8):1641-59.[2].TangQ,etal.ThemembranepermeablecalciumchelatorBAPTA-AMdirectlyblockshumanethera-go-go-relatedgenepotassiumchannelsstablyexpressedinHEK293cells.BiochemPharmacol.2007Dec3;74(11):1596-607.McePdfHeightCaution:Prod